With reference to Section 30 of the Danish Capital Markets Act, Gubra has received notifications from The Capital Group Companies on June 26, 2026, and June 29, 2026, respectively, regarding changes to its shareholding and voting rights position in Gubra. Following these notifications, The Capital Group Companies remains a major shareholder in Gubra.
The notifications were made by The Capital Group Companies, Inc. on behalf of affiliated investment management entities and funds under management. The reported holding relates to shares legally held by SMALLCAP World Fund, Inc., for which Capital Research and Management Company has been granted proxy voting authority.
Contacts
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Adam Lange (adl@gubra.dk, +45 6646 1589)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025. See www.gubra.dk for more information.